Recent studies suggest a permissive requirement for guanosine 5'-triphosphate (GTP) in insulin release, based on the use of GTP synthesis inhibitors (such as mycophenolic acid) acting at inosine monophosphate (IMP) dehydrogenase; herein, we examine the glucose dependency of GTP synthesis. Mycophenolic acid inhibited insulin secretion equally well after islet culture at 7.8 or 11.1 mM glucose (51% inhibition) but its effect was dramatically attenuated when provided at < 6.4 mM glucose (13% inhibition; P < 0.001). These observations were explicable by a stimulation of islet GTP synthesis derived from IMP since, at high glucose: (a) total GTP content was augmented; (b) a greater decrement in GTP (1.75 vs. 1.05 pmol/ islet) was induced by mycophenolic acid; and (c) a smaller "pool" of residual GTP persisted after drug treatment. Glucose also accelerated GTP synthesis from exogenous guanine ("salvage" pathway) and increased content of a pyrimidine, uridine 5'-triphosphate (UTP), suggesting that glucose augments production of a common regulatory intermediate (probably 5-phosphoribosyl-1-pyrophosphate). Pathway-specific radiolabeling studies confirmed that glucose tripled both salvage and de novo synthesis of nucleotides. We conclude that steep changes in the biosynthesis of cytosolic pools of GTP occur at modest changes in glucose concentrations, a finding which may have relevance to the adaptive ( patho ) physiologic responses of islets to changes in ambient glucose levels. (J. Clin. Invest.
Introduction
We recently reported that exocytotic insulin secretion from isolated, intact rat pancreatic islets depends upon an adequate islet content of guanosine 5'-triphosphate (GTP)' ( 1) .
The Journal of Clinical Investigation, Inc. Volume 92, August 1993, [872] [873] [874] [875] [876] [877] [878] [879] [880] [881] [882] The conclusion was based on the use of four selective inhibitors of inosine monophosphate (IMP) dehydrogenase (EC 1.1.1.205), a rate-limiting step in the de novo synthetic pathway for purine nucleotides. Two of these drugs, mycophenolic acid (MPA) and mizoribine, when provided during an 18-h culture period in RPMI 1640 (a purine-free medium), were shown to drastically curtail islet content of GTP and, pari passu, the subsequent insulin secretory responses to glucose and other secretagogues. MPA or mizoribine also caused a more modest inhibition of ATP content (by about 40%) and dramatic elevations of a pyrimidine, uridine 5'-triphosphate (UTP), presumably due to redirection of a precursor common to both pyrimidine and purine synthesis, such as 5-phosphoribosyl-1-pyrophosphate (PRPP). However, GTP was implicated as the regulatory factor since: (a) provision of exogenous adenine reversed changes in ATP and UTP, while leaving unaltered the decrements in GTP and in insulin release; and (b) provision of exogenous guanine, by fueling the "salvage" pathway for purine synthesis, restored both GTP and secretion nearly to normal levels. We concluded therefore that GTP was a permissive factor required for exocytotic insulin release ( 1 ).
In those studies, pancreatic islets were cultured overnight in 1. 1 mM (200 mg/dl) of glucose, since this usually is the most effective concentration for cultured islets to maintain insulin content and secretion (2, 3) . However, we were intrigued by an absence ofreports ofthe induction ofhyperglycemia in normal animals or humans treated with high concentrations of these drugs (e.g., MPA, provided as its pro-drug RS-61443, references 4 and 5) . Therefore, we questioned whether the ambient glucose concentration might modulate the islet content of purine nucleotides and, if so, whether glucose might alter the relative predominance ofthe pathways involved in the synthesis of GTP. The current studies (the first to our knowledge which address purine nucleotide metabolic pathways in peptide-secreting endocrine cells) provide data that support both possibilities and suggest that glucose alters purine nucleotide metabolism in both quantitative and qualitative fashions. The narrow range of relevant glucose concentrations over which such re- sponses can be discerned in pancreatic islets suggests that these events could have (patho)physiologic relevance to some of the islet's nucleotide-dependent adaptive responses to hyperglycemia, such as insulin secretion (1), RNA and protein synthesis (6) , and DNA synthesis (7 ( 1) indicated that MPA inhibits both phases of glucose-induced insulin release. The basal glucose concentration for acute incubations (i.e., after the overnight culture period) was 3.3 mM; the glucose concentration used to stimulate islets in all incubations was kept constant at 16.7 mM. MPA (or other test agents) was present during not only the culture period but also was included in islet picking, wash, or preincubation steps the following day, in order to avoid attenuation of its effects over time. However, drugs were excluded from the incubation period, since their effects were not rapidly dissipated after removal ( 1).
Insulin content andfractional release. After incubations to assess insulin release, the tubes containing islets, still resting on their polyethylene filters ( 15) , were placed in 1 5-ml conical centrifuge tubes containing 1 ml of acid alcohol (comprised of 77% absolute ethanol, 22% water, and 1% concentrated HCl; vol / vol), sonicated and left overnight at 4°C. After 20 h, one ml of phosphate-buffered saline and 30 Al of SN NaOH were added to raise the pH to 8.0, and the contents were vortexed after removing the glass tube but leaving behind the meshfilter so as to retain any islet tissue which might remain adherent to the filter. Tubes were centrifuged at 4°C for 5 min (X2,000 rpm); the supernatant was removed, diluted ( 1: 10) in RIA buffer (PBS) to a final dilution of 1:20, and assayed.
Insulin content of media or of islets was measured by RIA as described(l, [15] [16] [17] .
Determination of nucleotide content of islets. Islets were cultured overnight ( ( 1 ) . Values for basal islet nucleotide content were sufficiently constant (inter-experiment CVs of6.8, 7.2, and 10.8% for basal ATP, GTP, and UTP content, respectively) as to permit meaningful comparisons of the effect of experimental perturbations not only within, but also between, studies.
Labeling ofpurine nucleotides via the de novo or salvage pathways. In order to determine whether the de novo or salvage pathways contributed to the total GTP or ATP content, islets were labeled with 10 ACi/ml of [ 14C(U)]glycine (which donates carbons at position 4 and 5 , and nitrogen at position 7, of the newly-synthesized purine ring) or with 2 ,uCi/ml of [3H(G)]hypoxanthine (a substrate for HGPRTase) over an identical 18-h period. The added mass of hypoxanthine was kept low ('-120 nM), and labeled glycine replaced an equal mass of unlabeled glycine in the RPMI 1640 media, so as not to perturb the conditions under which ATP/GTP had been assessed by mass in the preceding studies; in addition, all other experimental conditions remained unchanged. After 18 h, islets were extracted and analyzed by HPLC as indicated (1) except that an additional rapid wash in 1 ml KRB buffer containing 0.5% BSA was added in order to remove more completely any unincorporated radiolabeled compounds adherent to the islets. Eluant fractions were collected every 30 s (glycine label) or every 18 s (hypoxanthine label) using a fraction collector (Multi-rac 21 1; LKB Instruments, Bromma, Sweden) and were matched against the exact times of elution of GTP and ATP using the concomitant UV chromatograms. Samples were counted for 5 min in 4 mls of scintillation cocktail.
Data presentation and statistical analysis. Absolute insulin secretion is expressed as ,uU/ 10 islets -45 min (mean±SEM) for static incubations. Incremental release is expressed as the value for insulin released under stimulated conditions (minus) the mean value for basal release (i.e., at 3.3 mM glucose) in that same study. Insulin content is expressed as AU/islet remaining at the end of the incubation period.
Some fractional release rates are also presented to take into account any effects on absolute rates of secretion caused by alterations in islet insulin content induced by agents such as MPA ( 1 where the denominator equals the insulin content remaining in islets at the end of the incubation period plus that insulin released during the incubation period. Fractional release is expressed as percent of initial insulin content released per 45 mins. Nucleotide content is expressed as pmol/islet; specific activity is expressed as dpm/ pmol. Increments or decrements in nucleotide content are expressed as the content ofeach experimental tube (minus) the mean content of the control tubes in that study; alternatively, experimental values are expressed in terms of percent of their mean control values (the glucose concentration used to define the "control" response for each experiment is indicated in the text or figure legends). Data are expressed as mean±SEM, with (n) representing the number of observations in a representative study, or the number of separate experiments, as indicated. Statistical analyses were by paired or nonpaired t tests, and ANOVA, as appropriate.
Results
Dependency on glucose concentration ofthe inhibition by MPA of glucose-induced insulin release. Glucose concentrations from 50-200 mg/dl (2.8-1 1.1 mM) were chosen for the overnight culture period. 25 ,ug/ml of MPA was used in all studies since it induces a maximal inhibition of GTP synthesis (1). It was confirmed ( 1 ) that an overnight exposure to MPA inhibits subsequent insulin release induced by 16.7 mM glucose; however, the inhibitory effect of MPA was influenced dramatically by the glucose concentration present during the preceding 18-h culture period (Fig. 1) . Islets cultured at 7.8 mM glucose were at least as sensitive to MPA as were islets cultured at 1 1.1 mM glucose, but sensitivity to MPA declined steeply at lower glucose concentrations, being half-maximal at 6.4 mM glucose, and essentially absent at 4.4 mM glucose (Fig. 1) . In paired analysis of data accrued within the same experiments, inhibition was always greater when MPA was provided at 7.8-1 1.1 mM glucose (-51±6%) than at <6.4 mM (-13±6%; P < 0.001 for six paired glucose-concentration comparisons within five separate experiments, as depicted by individual symbols in the inset to Fig. 1 ). In our cumulative experience using MPA (including data in reference 1 ), there was no overlap in the range of inhibition by MPA at higher glucose levels (range: 34 to 86%; n = 34 separate experiments) and that at lower glucose level (range: 0 to 34%; n = 6; P < 0.001 by nonpaired t test sure of islets to lower glucose levels, MPA reduced insulin content by only 7±3% (n = 5 experiments; P < 0.01; Table I ). In fact, at 2.8 mM glucose, MPA actually increased insulin content (Table I) . However, the effects of MPA on exocytotic release were independent of these effects of MPA on insulin content, since fractional insulin release (insulin release/insulin content) was also reduced much less by MPA during culture of islets at lower glucose levels (-14±7%; P = ns vs. no MPA) than after culture at 7.8-1 1.1 mM glucose (-44±5%; n = 5 experiments; P < 0.0001 vs. no MPA; P < 0.01 vs. inhibition by MPA at lower glucose levels; Table I ).
Effects ofglucose on GTP and A TP content, and their dependency on MPA-inhibitable pools. In order to explain the glucose dependency of MPA effects on secretion, the nucleotide content of islets was analyzed using a similar experimental paradigm. In addition, we estimated the proportion of the steady-state GTP (and ATP) content that was derived ultimately from IMP, by taking advantage of the facts that MPA is (Figs. 2-5) . Therefore, total NTP content also increased by 33% from 13.77±0.79 to 18.38±1.24 pmol/islet (df 11; P < 0.01 ). These effects were not explicable by a nonspecific (e.g., osmotic) effect of hexoses, since osmotic controls were present in all studies (see Methods); furthermore, the addition to 4.4 mM glucose of 6.7 mM 3-0-methylglucose (which is transported similarly to glucose but which is not metabolized; reference 25) actually slightly inhibited (by 5, 6, and 10%, respectively) content of GTP, ATP, and UTP (data not shown). Furthermore, the NTP content of islets declined if the glucose level was reduced from 4.4 to 1.7 mM glucose (Table   II) ; it fell to a comparable degree when 3.0 mM of mannoheptulose (which blocks the phosphorylation and further metabolism of glucose; reference 26) was added to 4.4 mM glucose during culture (Table II) .
Additionally, MPA reduced GTP or ATP content more at 1 1.1 mM glucose than at 4.4 mM glucose (both P < 0.001; Figs. 2, 3, and 5) . Thus, despite starting from higher levels at [Glucose] MPA ,25,ug/ml similar to those seen at 11.1 mM glucose alone (Fig. 5) , whereas, in contrast, no significant further rise in GTP (Fig. 5) or ATP was seen when guanine was provided at 1 1.1 mM glucose (Fig. 5) . However, when guanine (75 ,uM) was provided in the presence of MPA, islet content of GTP rose 65% more, and reached higher final levels (2.24±0.13 vs. 2.99±0.22; P < 0.05) at the higher glucose concentration despite again starting from a lower absolute level (P < 0.05) after MPA treatment (Fig. 5) . Likewise, guanine increased ATP content at 1 1.1 mM glucose only in the presence of MPA; ATP rose from 7.32±0.33 to 1 1.5±0.16 pmol/islet (P < 0.01 ). These findings support the formulation that a regulatory precursor (presumably PRPP) does indeed rise with high glucose levels but is shunted into IMP-dependent pathways; however, when this preferred pathway(s) is rendered unavailable due to the block imposed by MPA, the metabolite becomes free to fuel the guanine-induced "salvage" synthesis ofGTP as well (cf. references 27 and 28).
Effects ofglucose, MPA, and/or guanine on UTP content. The formulation above is supported by measurements ofUTP. MPA has been observed to induce a rise in cellular UTP content ( 1, 21, 29) attributable to an increase in the availability of PRPP2 ( 1, 27, 28, 30, 31 ) which is then shunted into the pyrimidine synthetic pathway. Therefore, we quantitated UTP during the current studies to assess indirectly whether glucose increases availability of precursors for NTP synthesis. A reduction in glucose concentration (from 4.4 to 1.7 mM) or the addition of mannoheptulose to 4.4 mM glucose reduced UTP in parallel to the changes in GTP and ATP (Table II) . Reciprocally, increasing glucose from 4.4 to 1 1.1 mM glucose nearly doubled UTP ( Fig. 4 ; Table III ). In the presence ofMPA, UTP levels rose by similar amounts at both glucose concentrations 2. PRPP content reflects changes in both its synthesis and consumption. MPA disinhibits PRPP synthesis (11, 31 ) by reducing purine nucleotide synthesis. In addition, IMP, which rises (23, 28) proximal to the MPA-induced block at IMP dehydrogenase (32), can be degraded to inosine (33, 34) which in islets (35) as in other tissues (4, 28, 31 ) is degraded to ribose-l-phosphate (36) . Ribokinase action converts ribose-I-phosphate to ribose-5-phosphate, which could increase synthesis of PRPP (33, 36) , which, in turn, is utilized for UTP synthesis. (Table IV) . By itself, guanine (30-100 ,qM) had little effect on subsequent secretion after culture, whether provided at 4.4 or 1 1.1 mM glucose (Table IV) . In contrast, in the presence of MPA, guanine increased (i.e., restored) insulin release in proportion to the degree of inhibition of GTP content and insulin release caused by MPA, i.e., to a large degree at 1 1.1 mM glucose and minimally, if at all, at 4.4 mM glucose (Table  IV) . Thus, guanine, via the salvage pathway, reverses the deficiency of pools ofGTP involved in exocytosis, which had been inhibited by MPA. Radiolabeling ofde novo or salvage GTP synthesis (Table  V) . These results together suggested that glucose augments flux into MPA-sensitive (i.e., IMP-derived) pool(s) of GTP. However, since IMP can be derived via several pathways, we ascertained directly whether de novo and salvage pathways contribute to GTP and ATP synthesis in islets. Purine nucleotide pools were labeled using ['4C]glycine (which is incorporated into nucleotides specifically via the de novo pathway) or [3H Ihypoxanthine (an index of salvage pathway activity), under conditions (see "Methods") essentially identical to those used to ascertain the bulk content (mass) of ATP/GTP in islets. Glucose progressively augmented the labeling of both nucleotides using either precursor (Fig. 6 ). High glucose ( 1 1.1 mM) increased the areas under the curve for the GTP peak to 208 and 331% of values at 4.4 and 1.7 mM glucose, respectively (labeled glycine) and to 190 and 279% (labeled hypoxanthine); corresponding values for ATP were 215 and 307% (labeled glycine) and 174 and 353% (labeled hypoxanthine) (Table V and Fig. 6 ). Similar changes were seen in the specific activities (dpm/pmol) of GTP or ATP (Table V) .
Discussion
Choice and relevance of experimental model. These studies were designed to determine whether islet GTP content, which has a permissive effect in exocytotic insulin release ( 1 ), is modified by the ambient glucose level. The experimental paradigm is based on the specific inhibition by MPA (or mizoribine) of IMP-dependent GTP synthesis, as assessed by steady-state GTP content (the biologically relevant parameter; reference 1). These drugs (8) (9) (10) (18) (19) (20) block the conversion of IMP to xanthosine monophosphate (XMP), possibly also reinforcing this effect by inhibiting conversion of XMP to guanine nucleotides ( [19] [20] [21] ), but without any direct effects on other nucleotide pathways (20) (21) (22) (23) (24) . RPMI 1640 was selected as the culture medium since it is purine-free (thus permitting manipulation of salvage pathway activity) and has an adequate concentration of inorganic phosphate (5.6 mM), which is a regulatory cofactor for synthesis of PRPP and of purine nucleotides ( 12, (37) (38) (39) (40) . 10% undialyzed FBS was provided as a potential source (33, 41, 42) ofsmall amounts ofhypoxanthine, in order to mimic the presence of the low amounts of hypoxanthine circulating in blood (43) (44) (45) . This amount of hypoxanthine supports a basal production of salvage pathway-derived nucleotides and thereby provides a physiologic restraint on the de novo pathway (41 ) without which the visualization ofa regulatory role for PRPP concentration in de novo pathway activity might be obfuscated (33) . Additionally, a narrow range of potentially relevant glucose concentrations was studied. However, as with any in vitro study, extrapolation of these findings to the situation in vivo should be made with caution. Effects ofMPA on GTP content and insulin release. In our previous studies at 1 1.1 mM glucose, a saturating concentration of MPA (25 ,ug/ml) reduced GTP by -80% and glucoseinduced insulin release by 54±2%. The current studies confirm these observations at nearly-normal glucose levels (7.8 mM) during the antecedent overnight culture period. A central new observation was that the inhibition of insulin release induced by MPA (or mizoribine) declined steeply at only slightly lower glucose levels, being half-maximal at 6.4 mM glucose and virtually absent at 4.4 mM. These studies suggest that even modest elevations in ambient glucose concentrations sensitize islets to inhibition by structurally dissimilar, selective inhibitors of IMP dehydrogenase. These findings imply that high glucose acts as a biologic "switch" to shunt nucleotide precursors preferentially into IMP-dependent pathways, rendering islet GTP content more susceptible to inhibition by the blockers. One might question whether the markedly blunted inhibition by MPA of insulin secretion seen after islet culture at lower glucose levels could be attributed to the relatively modest differences in the reduction ofGTP achieved by MPA (inhibition of GTP after 1 1.1 mM glucose = 80%; inhibition ofGTP after 4.4 mM glucose = 63%). However, this does indeed seem to be the case, since this effect of 25 ,tg/ml MPA at 4.4 mM glucose is (GTP: -60±2%; insulin secretion; -12%) in our previous studies ( 1 ) . In other words, MPA is only 1 / 50th as potent on exocytotic secretion at low as compared to higher glucose concentrations. This is because insulin release is not inhibited until GTP content falls (by > 80%) to a level of < 0.6-0.8 pmol/islet ( 1), but falls off precipitously thereafter. Thus, the lesser effect of MPA on insulin release after culture in lower glucose concentrations reflects a different origin (and therein a lesser inhibitability by MPA) ofthe GTP content. However, not only GTP derived via IMP but also that derived via the guanine salvage pathway is capable ofsupporting secretion, since exogenous guanine restores basal-and glucose-stimulated GTP levels in MPA-treated islets (current data) and, concomitantly, reverses the effect of MPA to inhibit insulin secretion (current data and reference 1). Thus, these studies provide no evidence ofa functional compartmentation of(MPA-sensitive vs. MPAinsensitive) cytosolic GTP pools with regard to exocytosis.
Effects ofglucose on nucleotide content. Increasing glucose levels modestly but consistently augmented total islet GTP content (by 40-50%, between 1.7 and 11.1 mM glucose). These findings are in accord with studies ofZunkler et al. (46) (48) who noted small changes in GTP content (or GTP/GDP ratio) within 30-150 min of marked increases in the glucose concentration to which pancreatic islets were exposed. Glucose also slightly (but again consistently) increased ATP levels and dramatically increased UTP levels. The most parsimonious explanation for these findings is that glucose increases the availability of PRPP, the precursor common to all three purine or pyrimidine nucleotides. Since the S05 (PRPP) for the de novo purine synthetic pathway is higher than the Km (PRPP) in the pyrimidine synthetic and purine salvage pathways ( 1 1, 12, 31,  32, 37, 38, 49) , and since PRPP availability is probably regulatory for all three ( 1 1, 41, 50, 5 1 ) , an increment in PRPP might (36, 41) , followed by the de novo synthetic pathway. Additionally, it is energetically reasonable ( 11 ) that salvage pathways would be preferred (41, 52) at lower levels of fuel availability (27, 36) , since, unlike the de novo3 pathway, it does not directly consume ATP. Effects of glucose on NTP content were seen not only upon increasing glucose concentration, but also, upon decreasing it or upon impeding glucose phosphorylation through the use of mannoheptulose. The latter findings, in conjunction with the lack of a stimulatory effect of 3-O-methylglucose, demonstrate that the glucose increases NTP content only after its metabolism, perhaps to ribose-5-phosphate (the precursor of PRPP).
The conclusion that glucose preferentially shunts GTP production from IMP-independent pathways to IMP-dependent pathways is supported by four findings: First, MPA, a selective inhibitor ofIMP dehydrogenase, reduced GTP content more at higher glucose levels. Second, MPA prevented the glucose-induced increment in GTP (and ATP). Third, the residual GTP remaining after MPA exposure4 was consistently smaller at higher glucose concentrations. Lastly, exogenous provision of guanine (to fuel the salvage pathways) stimulated a greater rise in GTP at higher glucose levels, but only when flux from IMP to GTP was prevented by treatment with MPA. In contrast, the 3 . In additional studies, we have documented that at the glucose levels studied, hypoxanthine salvage contributes more to the mass of GTP and ATP in islets than does the de novo synthetic pathway (Meredith, M., M. Rabaglia, and S. Metz, manuscript in preparation). 4 Relationship between GTP content and insulin secretion. In our studies, modest increments in GTP content induced by guanine at 4.4 mM glucose (to levels identical to those seen at 1 1.1 mM glucose alone; Fig. 5 ) had little effect on subsequent insulin release, suggesting that GTP levels must be close to saturating for secretion at physiologic glucose concentrations. In fact, a reduction of up to 60% in GTP content induced by submaximal concentrations of MPA (up to 0.1-1 ,g/ml) at 1 1.1 mM glucose ( 1 ) do not detectably impair subsequent secretion. However, when GTP content is inhibited more (see above) there is a steep decline in subsequent insulin secretory responses (and, reciprocally, a considerable rise in both GTP and insulin release when exogenous guanine is provided). Thus, under physiologic conditions, glucose availability may never become limiting for the GTP involved in insulin secretion (leading us to define its role as "permissive" only; reference 1). However, similar studies need to be carried out with regard to other glucose-dependent effects of purine nucleotides; for example, purine nucleotides are utilized for RNA synthesis (6) and DNA synthesis (7), which in turn are needed for islet protein synthesis and beta cell proliferation.
The rise in GTP (and in insulin secretion) induced by guanine, and the fall in both parameters induced by MPA, were in general, inversely proportional to the starting content ofpurine nucleotides, which are feedback inhibitors of salvage ( 11 ) and de novo ( 1 1, 31, 55 ) synthetic pathways as well as ofthe synthesis of their common precursor PRPP (1 1, 24, 41, [55] [56] [57] . Thus, our studies overall are quite compatible with data from other cells, which suggest that the cellular content of NTP is modulated by two interactive variables-the negative feedback control of nucleotides upon their own synthesis (at several enzymatic levels; references 11, 24, 31, [55] [56] [57] [58] and positive regulatory control by PRPP (27, 38, 41, 56) . Possible site(s) ofaction ofglucose on nucleotide synthesis. We hypothesized that glucose shunts substrates such as PRPP into IMP; however, it was unknown whether the two major pathways potentially yielding IMP (the de novo and salvage pathways) actually are present in islets. Therefore, we assessed their presence in islets via, respectively, the incorporation of [ I4C]glycine or [3H hypoxanthine into nucleotides. Our studies indicate that both pathways can generate ATP and GTP in islets and that glucose augments both their activities. The effect of glucose is even more impressive when one considers that glucose inhibits the uptake of glycine into islets (59) . Such labeling studies cannot be used to quantitate precisely the relative contributions3 of the two pathways to the abundance (mass) ofATP or GTP measured in islets; however, the considerably greater effect of glucose on the specific activity of GTP and/or ATP, compared to its effect on their total mass, suggests that these two pathways may, in fact, be selectively activated by glucose. This finding can be utilized profitably in future studies to assess more sensitively any acute effects of glucose on ATP or GTP synthesis.
